Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued
Reference number: GID-TA10418
The Department for Health and Social Care has asked NICE to carry out an appraisal of pembrolizumab within its marketing authorisation for treating advanced or metastatic urothelial cancer (with chemotherapy).
Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.